RaySearch’s 2012 Annual Report Published

Read original

As of today, the 2012 Annual Report of RaySearch Laboratories AB (publ) is available in Swedish as a pdf file on the company’s website www.raysearchlabs.com. The printed version in Swedish is now under distribution to the shareholders. The English version is under production and will be finalized in conjunction with RaySearch’s Annual General Meeting on Wednesday, May 22, 2013. Printed annual reports can be ordered from the company, telephone +46 (0)8-545 061 30.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA Dosimetry, Varian and Accuray. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Anders Martin-Löf, CFO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30
anders.martin-lof@raysearchlabs.com

About Us

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on Nasdaq Stockholm.

Subscribe

Documents & Links